Batool Zamani1, Seyed-Masoud Moeini Taba2, Mohammad Shayestehpour3,4. 1. Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. 2. Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. 3. Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. shayestehpour-m@kaums.ac.ir. 4. Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. shayestehpour-m@kaums.ac.ir.
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) is a complex and challenging autoimmune disease. Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel viral agent that can cause a life-threatening respiratory disorder named coronavirus disease 2019 (COVID‑19). Association between SARS‑CoV‑2 and SLE is not clear. We reported the first case of SLE manifestation following COVID-19. CASE PRESENTATION: A 39-year-old Iranian/Persian man with complaints of fever, scaling on the palms of the hands and feet, lower extremity edema, and ankle swelling was referred to Kashan Rheumatology Clinic in 2020. He was infected with SARS-CoV-2 2 months ago. The patient had proteinuria and was positive for SLE laboratory tests. After one week of treatment with prednisolone (30 mg daily) and hydroxychloroquine, paresthesia, proteinuria, and edema continued. The patient was treated with pulse methylprednisolone (1000 mg for three consecutive days), gabapentin, and vitamin B (300 mg daily), which reduced paresthesia. CONCLUSIONS: This is the first case of SLE manifestation following COVID-19. SARS-CoV-2 may produce autoantibodies or develop the clinical features of subclinical SLE.
BACKGROUND:Systemic lupus erythematosus (SLE) is a complex and challenging autoimmune disease. Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel viral agent that can cause a life-threatening respiratory disorder named coronavirus disease 2019 (COVID‑19). Association between SARS‑CoV‑2 and SLE is not clear. We reported the first case of SLE manifestation following COVID-19. CASE PRESENTATION: A 39-year-old Iranian/Persian man with complaints of fever, scaling on the palms of the hands and feet, lower extremity edema, and ankle swelling was referred to Kashan Rheumatology Clinic in 2020. He was infected with SARS-CoV-2 2 months ago. The patient had proteinuria and was positive for SLE laboratory tests. After one week of treatment with prednisolone (30 mg daily) and hydroxychloroquine, paresthesia, proteinuria, and edema continued. The patient was treated with pulse methylprednisolone (1000 mg for three consecutive days), gabapentin, and vitamin B (300 mg daily), which reduced paresthesia. CONCLUSIONS: This is the first case of SLE manifestation following COVID-19. SARS-CoV-2 may produce autoantibodies or develop the clinical features of subclinical SLE.
Authors: Rebecca B Blank; Rebecca H Haberman; Kun Qian; Marie Samanovic; Rochelle Castillo; Anthony Jimenez Hernandez; Parvathy Vasudevapillai Girija; Sydney Catron; Zakwan Uddin; Paula Rackoff; Gary Solomon; Natalie Azar; Pamela Rosenthal; Peter Izmirly; Jonathan Samuels; Brian Golden; Soumya Reddy; Mark J Mulligan; Jiyuan Hu; Jose U Scher Journal: Rheumatology (Oxford) Date: 2022-05-28 Impact factor: 7.046
Authors: J Tyson McDonald; Francisco J Enguita; Deanne Taylor; Robert J Griffin; Waldemar Priebe; Mark R Emmett; Mohammad M Sajadi; Anthony D Harris; Jean Clement; Joseph M Dybas; Nukhet Aykin-Burns; Joseph W Guarnieri; Larry N Singh; Peter Grabham; Stephen B Baylin; Aliza Yousey; Andrea N Pearson; Peter M Corry; Amanda Saravia-Butler; Thomas R Aunins; Sadhana Sharma; Prashant Nagpal; Cem Meydan; Jonathan Foox; Christopher Mozsary; Bianca Cerqueira; Viktorija Zaksas; Urminder Singh; Eve Syrkin Wurtele; Sylvain V Costes; Gustavo Gastão Davanzo; Diego Galeano; Alberto Paccanaro; Suzanne L Meinig; Robert S Hagan; Natalie M Bowman; Matthew C Wolfgang; Selin Altinok; Nicolae Sapoval; Todd J Treangen; Pedro M Moraes-Vieira; Charles Vanderburg; Douglas C Wallace; Jonathan C Schisler; Christopher E Mason; Anushree Chatterjee; Robert Meller; Afshin Beheshti Journal: Cell Rep Date: 2021-09-30 Impact factor: 9.423